New US legislation, backed by trade group Innovation Organization (BIO), to free up capital for small innovative firms by ...

Italian non-profit rare and complex genetic diseases specialist Fondazione Telethon (FT) and Orphan Therapeutics Accelerator ...

California-based Tenaya Therapeutics, a biotech seeking to discover, develop and deliver potentially curative therapies that ...

The US Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for copper ...

One of the biggest challenges to the cell and gene therapy (CGT) landscape over the last couple of years has been the ...

As many as four out of 10 assessments of new drugs carried out by the Danish Medicines Council had the process stopped midway ...

Results from the PERSEUS Phase III study showed that tolebrutinib did not meet its primary endpoint in delaying time to ...

US biopharma Arcus Biosciences has announced the discontinuation of the Phase III STAR-221 study, being conducted in ...

Swedish rare disease specialist Hansa Biopharma announced a reorganization of its European and International Commercial and ...

Japan’s Tanabe Pharma, formerly known as Mitsubishi Tanabe and now owned by Bain Capital, has obtained approval from the ...

Swedish Orphan Biovitrum, also known as Sobi, has entered into a definitive agreement to acquire San Diego, USA-based biotech ...

On December 12, 2025, the US Food and Drug Administration approved Johnson & Johnson subsidiary Janssen Biotech’s Akeega (niraparib and abiraterone acetate with prednisone for adults with deleterious ...